The latest price target for Mustang Bio (NASDAQ:MBIO) was reported by HC Wainwright & Co. on May 16, 2024. The analyst firm set a price target for $2.00 expecting MBIO to rise to within 12 months (a possible 1054.73% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Mustang Bio (NASDAQ:MBIO) was provided by HC Wainwright & Co., and Mustang Bio reiterated their buy rating.

There is no last upgrade for Mustang Bio

There is no last downgrade for Mustang Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mustang Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mustang Bio was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.

While ratings are subjective and will change, the latest Mustang Bio (MBIO) rating was a reiterated with a price target of $2.00 to $2.00. The current price Mustang Bio (MBIO) is trading at is $0.17, which is out of the analyst’s predicted range.